首页> 外文OA文献 >Phenotype diversity in type 1 Gaucher disease: discovering the genetic basis of Gaucher disease/hematologic malignancy phenotype by individual genome analysis
【2h】

Phenotype diversity in type 1 Gaucher disease: discovering the genetic basis of Gaucher disease/hematologic malignancy phenotype by individual genome analysis

机译:1型Gaucher病的表型多样性:通过个体基因组分析发现Gaucher病/血液系统恶性表型的遗传基础

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Gaucher disease (GD), an inherited macrophage glycosphingolipidosis, manifests with an extraordinary variety of phenotypes that show imperfect correlation with mutations in the GBA gene. In addition to the classic manifestations, patients suffer from increased susceptibility to hematologic and nonhematologic malignancies. The mechanism(s) underlying malignancy in GD is not known, but is postulated to be secondary to macrophage dysfunction and immune dysregulation arising from lysosomal accumulation of glucocerebroside. However, there is weak correlation between GD/cancer phenotype and the systemic burden of glucocerebroside-laden macrophages. Therefore, we hypothesized that genetic modifier(s) mayunderlie the GD/cancer phenotype. In the present study, the genetic basis of GD/T-cell acute lymphoblastic lymphoma in 2 affected siblings was deciphered through genomic analysis. GBA gene sequencing revealed homozygosity for a novel mutation, D137N. Whole-exome capture and massively parallel sequencing combined with homozygosity mapping identified a homozygous novel mutation in the MSH6 gene that leads to constitutional mismatch repair deficiency syndrome and increased cancer risk. Enzyme studies demonstrated that the D137N mutation in GBA is a pathogenic mutation, and immunohistochemistry confirmed the absence of the MSH6 protein. Therefore, precise phenotype annotation followed by individual genome analysis has the potential to identify genetic modifiers of GD, facilitate personalized management, and provide novel insights into disease pathophysiology. (Blood. 2012; 119(20):4731-4740)
机译:高雪氏病(GD)是一种遗传性巨噬细胞糖鞘脂病,表现出多种表型,表现出与GBA基因突变的不完美关联。除经典表现外,患者还易患血液系统和非血液系统恶性肿瘤。 GD恶性肿瘤的潜在机制尚不清楚,但被认为是继发于葡萄糖脑溶酶体溶酶体积聚引起的巨噬细胞功能障碍和免疫失调的继发机制。然而,GD /癌症表型与糖苷脑苷脂的巨噬细胞的全身负担之间的相关性较弱。因此,我们假设遗传修饰剂可能是GD /癌症表型的基础。在本研究中,通过基因组分析破译了2个患病兄弟姐妹中GD / T细胞急性淋巴细胞性淋巴瘤的遗传基础。 GBA基因测序揭示了新突变D137N的纯合性。全外显子捕获和大规模平行测序与纯合定位相结合,鉴定出MSH6基因中的纯合新突变,该突变导致体质错配修复缺陷综合征并增加了癌症风险。酶研究表明,GBA中的D137N突变是一种致病性突变,免疫组织化学证实没有MSH6蛋白。因此,随后进行个体基因组分析的精确表型注释具有识别GD的遗传修饰因子,促进个性化管理以及对疾病病理生理学提供新颖见解的潜力。 (2012年血液; 119(20):4731-4740)

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号